IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review

Varun Chaudhary, Frédéric Matonti, Javier Zarranz-Ventura, Michael W Stewart, Varun Chaudhary, Frédéric Matonti, Javier Zarranz-Ventura, Michael W Stewart

Abstract

Purpose: Understanding the impact of fluid in different retinal compartments is critical to developing treatment paradigms that optimize visual acuity and reduce treatment burden in neovascular age-related macular degeneration. This systematic review aimed to determine the impact of persistent/new subretinal fluid, intraretinal fluid, and subretinal pigment epithelial fluid on visual acuity over 1 year of treatment.

Methods: Publication eligibility and data extraction were conducted according to Cochrane methods: 27 of the 1,797 screened records were eligible.

Results: Intraretinal fluid negatively affected visual acuity at baseline and throughout treatment, with foveal intraretinal fluid associated with lower visual acuity than extrafoveal intraretinal fluid. Some studies found that subretinal fluid (particularly subfoveal) was associated with higher visual acuity at Year 1 and longer term, and others suggested subretinal fluid did not affect visual acuity at Years 1 and 2. Data on the effects of subretinal pigment epithelial fluid were scarce, and consensus was not reached. Few studies reported numbers of injections associated with fluid status.

Conclusion: To optimally manage neovascular age-related macular degeneration, clinicians should understand the impact of fluid compartments on visual acuity. After initial treatment, antivascular endothelial growth factor regimens that tolerate stable subretinal fluid (if visual acuity is stable/improved) but not intraretinal fluid may enable patients to achieve their best possible visual acuity. Confirmatory studies are required to validate these findings.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.

Figures

Fig. 1.
Fig. 1.
PRISMA flow diagram.

References

    1. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014;98:1144–1167.
    1. Brown DM, Kaiser PK, Michels M, et al. . Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444.
    1. Martin DF, Martin DF, Maguire MG, et al. . Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–1398.
    1. Martin DF, Martin DF, Maguire MG, et al. . Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–1908.
    1. Rosenfeld PJ, Brown DM, Heier JS, et al. . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
    1. Waldstein SM, Wright J, Warburton J, et al. . Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology 2016;123:60–69.
    1. Simader C, Ritter M, Bolz M, et al. . Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 2014;121:1237–1245.
    1. Schmidt-Erfurth U, Bogunovic H, Sadeghipour A, et al. Machine learning to analyze the prognostic value of current imaging biomarkers in neovascular age-related macular degeneration. Ophthalmol Retina 2018;2:24–30.
    1. Ying GS, Kim BJ, Maguire MG, et al. . Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 2014;132:915–921.
    1. Jaffe GJ, Ying GS, Toth CA, et al. . Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology 2019;126:252–260.
    1. Guymer RH, Markey CM, McAllister IL, et al. . Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology 2019;126:723–734.
    1. Waldstein SM, Bogunovic H, Sadeghipour A, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology 2016;123:1521–1529.
    1. Jaffe GJ, Martin DF, Toth CA, et al. . Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;120:1860–1870.
    1. Sharma S, Toth CA, Daniel E, et al. . Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology 2016;123:865–875.
    1. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions; Chichester, United Kingdom: John Wiley & Sons, 2019.
    1. Ying GS, Huang J, Maguire MG, et al. . Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122–129.
    1. Regillo CD, Busbee BG, Ho AC, et al. . Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration. Am J Ophthalmol 2015;160:1014–1023.e2.
    1. Ritter M, Simader C, Bolz M, et al. . Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. Br J Ophthalmol 2014;98:1629–1635.
    1. Kodjikian L, Decullier E, Souied EH, et al. . Predictors of one-year visual outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. Retina 2018;38:1492–1499.
    1. Schmidt-Erfurth U, Vogl WD, Jampol LM, Bogunović H. Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration. Ophthalmology 2020;127:1211–1219.
    1. Ying GS, Maguire MG, Pan W, et al. . Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials. Ophthalmol Retina 2018;2:525–530.
    1. Wickremasinghe SS, Sandhu SS, Busija L, et al. . Predictors of AMD treatment response. Ophthalmology 2012;119:2413–2414. e2415.
    1. Wickremasinghe SS, Janakan V, Sandhu SS, et al. . Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol. Retina 2016;36:1331–1339.
    1. Dervenis N, Younis S. Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration. Clin Ophthalmol 2016;10:1117–1122.
    1. Inan S, Polat O, Karadas M, Inan UU. The association of exudation pattern with anatomical and functional outcomes in patients with neovascular age-related macular degeneration. Rom J Ophthalmol 2019;63:238–244.
    1. Pokroy R, Mimouni M, Barayev E, et al. . Prognostic value of subretinal hyperreflective material in neovascular age-related macular degeneration treated with bevacizumab. Retina 2018;38:1485–1491.
    1. Chatziralli I, Nicholson L, Vrizidou E, et al. . Predictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly aflibercept. Ophthalmology 2016;123:1762–1770.
    1. Kim JH, Chang YS, Kim JW. Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina 2017;37:2254–2261.
    1. Chakravarthy U, Pillai N, Syntosi A, et al. . Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye (Lond) 2020;34:2249–2256.
    1. de Massougnes S, Dirani A, Mantel I. Good visual outcome at 1 year in neovascular age-related macular degeneration with pigment epithelium detachment: factors influencing the treatment response. Retina 2018;38:717–724.
    1. Ogasawara M, Koizumi H, Yamamoto A, et al. . Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2018;62:584–591.
    1. Ersoy L, Ristau T, Kirchhof B, Liakopoulos S. Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2014;252:889–897.
    1. Bringmann A, Wiedemann P. Müller glial cells in retinal disease. Ophthalmologica 2012;227:1–19.
    1. Riedl S, Cooney L, Grechenig C, et al. . Topographic analysis of photoreceptor loss correlated with disease morphology in neovascular age-related macular degeneration. Retina 2020;40:2148–2157.
    1. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 2016;50:1–24.
    1. Ebneter A, Gekkiev B, Chanana B, et al. . The presence of intra- or subretinal fluid during the loading phase in the treatment of exudative age-related macular degeneration with intravitreal ranibizumab assessed by optical coherence tomography. Ophthalmologica 2015;234:61–66.
    1. Jaffe GJ, Kaiser PK, Thompson D, et al. . Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology 2016;123:1856–1864.
    1. Lin T, Dans KC, Muftuoglu IK, et al. . Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. Br J Ophthalmol 2020;104:58–63.
    1. Shin JY, Woo SJ, Ahn J, Park KH. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography. Korean J Ophthalmol 2013;27:425–432.
    1. Gianniou C, Dirani A, Jang L, Mantel I. Refractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intravitreal ranizubimab: functional and structural outcome. Retina 2015;35:1195–1201.
    1. Jang L, Gianniou C, Ambresin A, Mantel I. Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. Graefes Arch Clin Exp Ophthalmol 2015;253:1211–1216.
    1. Curry B, Bylsma G, Hewitt AW, Verma N. The VEGF treatment of AMD switch study (the vTAS study). Asia Pac J Ophthalmol (Phila) 2017;6:481–487.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する